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Acute myocardial infarction (MI) is a primary cause of worldwide morbidity and mortality.
Macrophages are fundamental components of post-MI inflammation. Pro-inflammatory
macrophages can lead to adverse cardiac remodeling and heart failure while anti-inflamma-
tory/reparative macrophages enhance tissue healing. Shifting the balance between pro-
inflammatory and reparative macrophages post-MI is a novel therapeutic strategy. Azithro-
mycin (AZM), a commonly used macrolide antibiotic, polarizes macrophages towards the
anti-inflammatory phenotype, as shown in animal and human studies. We hypothesized that
AZM modulates post-MI inflammation and improves cardiac recovery.
Methods and results
Male WT mice (C57BL/6, 6–8 weeks old) were treated with either oral AZM (160 mg/kg/day)
or vehicle (control) starting 3 days prior to MI and continued to day 7 post-MI. We observed
a significant reduction in mortality with AZM therapy. AZM-treated mice showed a significant
decrease in pro-inflammatory (CD45+/Ly6G-/F4-80+/CD86+) and increase in anti-inflamma-
tory (CD45+/Ly6G-/F4-80+/CD206+) macrophages, decreasing the pro-inflammatory/anti-
inflammatory macrophage ratio in the heart and peripheral blood as assessed by flow
cytometry and immunohistochemistry. Macrophage changes were associated with a signifi-
cant decline in pro- and increase in anti-inflammatory cytokines. Mechanistic studies con-
firmed the ability of AZM to shift macrophage response towards an anti-inflammatory state
under hypoxia/reperfusion stress. Additionally, AZM treatment was associated with a
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distinct decrease in neutrophil count due to apoptosis, a known signal for shifting macro-
phages towards the anti-inflammatory phenotype. Finally, AZM treatment improved cardiac
recovery, scar size, and angiogenesis.
Conclusion
Azithromycin plays a cardioprotective role in the early phase post-MI through attenuating
inflammation and enhancing cardiac recovery. Post-MI treatment and human translational
studies are warranted to examine the therapeutic applications of AZM.
Introduction
Acute myocardial infarction (MI) is a leading cause of mortality and morbidity in the western
world [1]. MI provokes a profound coordinated inflammatory response, a process mediated
by inflammatory bone marrow (BM) and peripheral blood (PB) cells, which has been linked to
the development of end stage heart failure (HF), a highly frequent complication post-MI [1].
The peri-infarct zone demonstrates dynamic cellular changes with the infiltration of various
inflammatory cells including neutrophils, monocytes, and macrophages [2]. Monocytes infil-
trate the peri-infarct zone and differentiate into macrophages, which play an important role in
the initial inflammatory as well as the following reparatory phases [3]. Two dominant patterns
of macrophage activation are found: pro-inflammatory/classically activated macrophages
(M1-like) and anti-inflammatory/alternatively activated/reparative macrophages (M2-like),
with different cell markers and gene expression profiles [2]. In mice, the initial exaggerated
inflammatory response may actually confer long-term harm because reductions in the initial
recruitment of inflammatory monocytes reduce infarct size and prevent adverse cardiac
remodeling [4, 5]. Pro-inflammatory macrophages trigger inflammation, damage of extra cel-
lular matrix (ECM) [6], production of reactive oxygen/ nitrogen species and pro-inflammatory
cytokines (IL-6, TNF-α, and IL-1β) [7]. In contrast, anti-inflammatory macrophages promote
ECM repair, angiogenesis, and production of anti-inflammatory cytokines (IL-4, IL-10, and
IL-13) [8, 9].
Azithromycin (AZM), a clinically approved macrolide antimicrobial agent, has an excellent
safety profile in humans [10]. AZM modulates the inflammatory response through macro-
phage polarization towards the reparative state [11, 12], as demonstrated in models of inflam-
mation and tissue injury such as spinal cord injury [13], lung infection [14], and stroke [15].
In these clinically relevant scenarios, AZM reduces the production of pro-inflammatory cyto-
kines (IL-6 and IL-12) and increases that of anti-inflammatory cytokines (IL-10) [12]. Addi-
tionally, AZM significantly decreased the expression of iNOS and pro-inflammatory
macrophage receptor (CCR7) while increasing arginase activity and anti-inflammatory macro-
phage receptors (MR and CD23) [12]. In an ischemic stroke model, which induces a similar
sterile inflammatory response to MI, AZM shifted macrophages from the pro-inflammatory to
the reparative state leading to inhibition of blood brain barrier injury and improvement in
neurological recovery [15]. Likewise, in a retinal ischemia/reperfusion experimental model,
AZM was protective against neuronal injury. This protection was attributed to the anti-inflam-
matory properties of AZM, as evidenced by the reduction in MMP-9/2 expression and activity
[16]. In addition to its immunomodulatory properties, AZM is well tolerated, achieves a wide
therapeutic index, and has well characterized pharmacokinetic and pharmacodynamic proper-
ties [10].
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Here, we provide the first evidence that AZM reduces the inflammatory response and medi-
ates cardioprotection against adverse cardiac remodeling and HF post-MI. AZM produces its
positive effects through increasing neutrophil apoptosis and switching macrophage activation
towards an anti-inflammatory phenotype. Our findings present an important step towards
designing clinically relevant strategies to reduce the risk of cardiac remodeling and HF after
MI.
Materials and methods
Study Design. 8–10 weeks male C57BL/6 mice (Jackson Laboratory, BarHarbor, ME) were
treated with either AZM (Azithromycin tablets, USP, Sandoze, NDC0781194133, Princeton,
NJ), (crushed tablets suspended in 2% methylcellulose), orally using gastric gavage at 160 mg/
kg/day or vehicle (2% methylcellulose), starting 3 days prior to MI or sham surgeries through
day 7 post-MI (Fig 1A). Timing of AZM therapy was selected to ensure appropriate steady-
state levels at the time of injury [14]. AZM administration was continued for 7 days after sur-
gery to cover the entire duration of post-MI inflammatory response [17, 18]. AZM treatment
was not associated with changes in liver or kidney function throughout the period of adminis-
tration (S1 Fig). All procedures were conducted under the approval of the University of Ken-
tucky IACUC in accordance with the NIH Guide for the Care and Use of Laboratory Animals
(DHHS publication No. [NIH] 85–23, rev. 1996).
Murine model of myocardial infarction
Mice were anesthetized with 1–3% isoflurane using a small animal vaporizer system. Pain
reflexes were examined to make sure that the mouse is adequately anaesthetized prior to sur-
gery. Following a left thoracotomy between the fourth and fifth ribs and removal of pericardial
sac, the heart was exposed and pushed out of the thorax under direct visualization. The left
anterior descending coronary artery (LAD) was identified under a surgical microscope and
permanently ligated 3 mm below its origin using a 6–0 silk suture as previously described [19,
20]. The sham group underwent the same surgical procedure except the suture was passed
under the LAD but not tied. Following LAD ligation, the heart was placed back into the intra-
thoracic space and the pneumothorax was manually evacuated. After muscle closure, the skin
was sutured using 4–0 Prolene running sutures.
Humane endpoints
Animals were treated with pain medications for 24–48 hours after surgery. This duration may
be prolonged if animals showed signs of pain, discomfort or reduced food or water intake.
Animals were followed every 8 hours for 24 hours followed by daily for 1 week, for any signs of
clinical deterioration or overt heart failure. Their water and food consumption is monitored
carefully. Any animals that show signs of decompensation were resuscitated and if this is
unsuccessful, they were humanly euthanized. We also monitored mice for additional signs of
distress or weight loss >15–20% from baseline weight; hunched posture; ruffled coat; etc. If
the mice exhibited any of these signs, they were euthanized without any subsequent experi-
mental procedures. Most of the mortality in our MI group occurred in the first week after sur-
gery. Necropsy showed blood filled thoracic cavity suggesting myocardial rupture as the cause
of death.
The appearance of the surgical site is checked for signs of infection, undue sutures, and ser-
oma formation. When possible, infection, sutures, or seroma formation is treated medically
(antibiotics, if indicated) or surgically (replacing sutures or percutaneous drainage, respec-
tively). In rare cases in which infection appears to have occurred, we consulted with DLAR
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Fig 1. AZM therapy shifts macrophages towards the anti-inflammatory phenotype in the heart after myocardial infarction. Experimental design for the in vivo study
(Panel A). Representative FACS plots demonstrating the gating strategy for pro-inflammatory (CD45+/Ly6G+/F4-80+/CD86+) and anti-inflammatory (CD45+/Ly6G+/F4-
80+/CD206+) macrophages (Panel B). Quantitative analyses of pro-inflammatory subpopulations (CD86+) and anti-inflammatory subpopulations (CD206+) are presented in
Panels C and D, respectively, at different time points following MI in AZM and vehicle treated groups. There is a significant reduction in the inflammatory macrophages in
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veterinary for advise, treatment and management. In cases where complications are felt to be
causing the animal significant distress, the animal is euthanized.
Method of euthanasia
Mice were euthanized using high dose isoflurane followed by cervical dislocation to confirm
their euthanasia.
Flow cytometry
Peripheral blood tubes containing 1:5 ratios of ethylene diaminetetraaceticacid (EDTA)/cit-
rate-theophylline-adenosinedipyridamole (CTAD) were used to collect blood samples at 1, 3
and 7 days after MI (4 MI mice and 3 sham mice /treatment group). Whole blood was centri-
fuged at 700g for 5 minutes, and plasma layer was collected in separated tubes and kept at
-80˚C. The remaining cell pack was incubated with 0.5 ml of 1X of red blood lysing buffer (BD
pharm lyse) for 10 minutes with gentle agitation for RBC lysis followed by dilution using 0.5
ml of staining buffer (5% goat serum, 0.05% sodium azide in phosphate-buffered saline) to
stop the reaction. The suspension was centrifuged at 400g for 5 minutes, and supernatant was
discarded. This step was repeated if we observed residual red blood cells. The white blood cell
pellet was resuspended in staining buffer, washed to remove any remaining of lysis buffer, and
centrifuged at 400g for 5 minutes. Cells from individual blood samples were split into two por-
tions for flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR) based
on cell counts so that each sample contained *106 live (trypan blue-negative) cells. Cells for
rtPCR were lysed using cell lysis buffer (Life technologies) for 10 minutes with strong agitation
and kept at -80˚C for gene analyses. Cells for staining were immediately incubated on ice for
30 minutes with conjugated primary antibodies against FITC-conjugated Ly6G/C (BD Phar-
mingen), APC-CY7-conjugated CD45 (Biolegend), PE-conjugated CD115 (Biolegend) for the
monocyte panel. After incubation, cells were washed twice using flow buffer and analyzed
using an LSR II (Becton Dickinson) in the University of Kentucky Flow Cytometry Core.
Monocytes were classified as pro-inflammatory (CD45+/CD115hi/Ly6-Chi) and anti-inflam-
maory (CD45+/CD115hi/Ly6-Clo). Neutrophils were identified as CD45+/CD115lo/Ly6G/Clo.
Heart tissue collected at the same time points were rapidly removed and placed in ice cold
PBS (VWR International). The heart was manually minced using razor blades. Minced heart
tissue was transferred into 15 ml tube with Collagenase B (Roche, Indianapolis, IN) and Dis-
pase II (Roche, Indianapolis, IN) solution for 30 minutes in 37˚C water bath, with manual agi-
tation every 5–10 minutes. Then, the digestion reaction was terminated using cold staining
buffer, and tubes were placed in ice. The digestion mixture was filtered through 70 μm cell
strainers and centrifuged at 400g for 5 min at 4 0C, then the supernatant was aspirated and
cells were resuspended in 0.5 ml of staining buffer. Cells from individual hearts were split into
approximately three portions based on cell counting so that each sample contained *106 live
(trypan blue-negative) cells for flow cytometry and RT-PCR as detailed above. Cells were incu-
bated directly on ice for 30 minutes with conjugated primary antibodies against FITC-conju-
gated Ly6G (BD Pharmingen), PE-conjugated CD206 (Biolegend), PerCP-CY5.5-conjugated
CD86 (Biolegend), PECY7-conjugated F4/80 (Biolegend), and APC-CY7-conjugated CD45
(Biolegend) for the macrophage panel, or the monocyte panel detailed above. After incubation,
the first day after MI in AZM-treated mice, which is associated with a significant increase in anti-inflammatory ones. These changes translate into a significant reduction in
the pro-/anti-inflammatory (CD86+/ CD206+) ratio at days 1 and 3 after MI (Panel E) (n = 4 MI and 3 sham mice/group/time point, P<0.05, P<0.01 and P<0.001
compared to vehicle controls). Data presented as mean ± SEM. AZM, azithromycin; IHC, immunohistochemistry; LAD, left anterior descending coronary artery; rtPCR,
real-time Polymerase Chain Reaction.
https://doi.org/10.1371/journal.pone.0200474.g001
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cells were washed twice using flow buffer and analyzed using an LSR II (Becton Dickinson).
Macrophages were classified into pro-inflammatory (CD45+/Ly6G-/F4-80+/CD86+ cells) and
ant-inflammatory (CD45+/Ly6G-/F4-80+/CD206+ cells). Laser calibration and compensation
were carried out for every experiment utilizing unstained and single fluorescent controls.
Using the same protocols mentioned earlier, cells isolated from hearts and peripheral blood
were incubated with APC-CY7-conjugated CD45 (Biolegend), FITC-conjugated Ly6G (BD
Pharmingen), APC-conjugated Annexin 5 (Biolegend) and PE-conjugated propidium iodide
(PI) (Biolegend) to identify apoptosis in neutrophils. Cells were considered apoptotic if they
were PIlo/Annexin Vhi. For flow analyses in all experiments we utilized FlowJo (version 7) soft-
ware to generate dot plots and analyze the data.
Histology
Mice (N = 12-15/treatment group) were sacrificed 30 days after MI and hearts were collected
in diastole by using saturated KCl and CdCl2 (100 mM) given through the apex into the left
ventricular (LV) cavity. Then we cannulated the ascending aorta and perfused the heart with
PBS (VWR International) followed by 10% buffered formalin (VWR International) at 75
mmHg. Hearts were placed in 5 ml of 10% neutral buffered formalin (VWR) and fixed over-
night at room temperature. Hearts were then sectioned into 2-mm cross-sectional slices fol-
lowed by paraffin embedding. Tissue was transferred to 70% ethanol for overnight followed by
sectioning into 4-μm sections starting at the level of LAD ligation. Sections were then stained
with Masson’s trichrome to evaluate scar size. Digital images were taken, and areas were evalu-
ated using NIH ImageJ (version 7). We measured the LV area, LV cavity area, and infarct area
in stained sections, as previously described [19, 20]. The scar size was presented as a percentage
of LV myocardial volume.
Immunohistochemistry
Mice (N = 4/treatment group) were sacrificed 3 days after MI and hearts were collected.
Immunohistochemical assessments were carried out on deparaffinized and rehydrated sec-
tions as previously described [20]. After deparaffinization and washing, slides were incubated
with primary antibodies: rat anti-mouse CD86 (1:100, BD Biosciences), goat anti-mouse
CD206 (1:1000, R and D Systems), rabbit anti-mouse YM1 (1:25, Stem Cell technologies), and
goat anti-mouse IL-1β (1:200 R & D System) overnight at 4˚C. After washing, sections were
incubated with secondary antibodies conjugated to Alexa Fluor 594,647 (1:500, Invitrogen,
Carlsbad, CA), then incubated with Sudan Black B (Sigma Aldrich, St. Louis, MO) for 30 min-
utes. and subsequently incubated with DAPI nuclear counterstain. 10–15 adjacent areas in the
pre-infarct and remote zones per section were analyzed (1–2 sections/animal) at 40x magnifi-
cation using Nikon Confocal Microscope A1 in the University of Kentucky Confocal Micros-
copy facility. Only nucleated antibody positive cells were counted. Calculations were
performed using the Cell Counter plugin for ImageJ (version 1.51d). Data were presented as
total positive cells per high power field in the region of interest.
A similar protocol was used to prepare heart sections from mice on day 30 for angiogenesis
assessment using FITC- isolectin B4 (FL1201, Vector Labs, Burlingame, CA). 10–15 adjacent
areas in the pre-infarct per section were examined (1–2 sections/animal) at 40x magnification
using Nikon Confocal Microscope A1 in the University of Kentucky Confocal Microscopy
facility. Data were presented as total capillary density per mm2 in the peri-infarct region. All
measurements were analyzed by blinded observers.
To examine apoptosis in heart tissue, we used a TdT dUDP Nick-End Labeling (TUNEL)
Assay and Caspase-3 staining. Caspase 3 staining was done in deparaffinized and rehydrated
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sections using antibody against cleaved caspase 3 as previously described [20]. TUNEL staining
was performed in Biospecimen Procurement and Translational Pathology Shared Resource
Facility (BPTP SRF) at the University of Kentucky. Only nucleated positive cells were counted
in the peri-infarcted and infarcted areas. Calculations were done using the Cell Counter plugin
for ImageJ (version 1.51d). Data were presented as total positive cells per high power field in
the region of interest. All measurements were analyzed by blinded observers.
Real-time polymerase chain reaction
We utilized PureLink RNA Mini Kit (ThermoFisher Scientific) to collect total RNA from heart
and blood cells according to the manufacturer’s protocol. The extracted RNA was quantified
using NanoDrop 8000 spectrophotometer (Thermofisher). Then, cDNA was synthesized using
SuperScript VILO cDNA synthesis kit (Invitrogen). Quantitative RT-PCR was performed
using a QuantaStudio 7 Flex real-time thermocycler (Applied Biosystems by life technology) to
quantify the mRNA expression of markers identifying: inducible nitric oxide synthases
(iNOS), tumor necrosis factor alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1),
transforming growth factor beta (TGF-β), interleukin-1 beta (IL-1β), interleukin-6 (IL-6),
interleukin-4 (IL-4), chitinase-like3 Chil3 (YM1), Peroxisome proliferator-activated receptor
gamma (PPARg). We used the comparative Ct method for relative estimation of mRNA
expression which were normalized to 18s (a housekeeping gene). To overcome the possible
errors due to augmentation of contaminated DNA: (a) we used primers adjusted to bridge an
intron for specific cDNA augmentation; (b) we used proper negative control reactions (tem-
plate free controls); (c) we reassessed the consistency of product augmentation through exami-
nation of the melting curve of augmented products (dissociation graphs); and (d) the melting
temperature (Tm) was 57˚C–60˚C, and the probe Tm was at least 10˚C more than the primer
Tm. The primer sequences are listed in S1 Table.
Echocardiography
We used a Vevo 3100 system supplied with a 15-7-MHz linear broadband transducer and a
12-5-MHz phased array transducer to acquire Echocardiograms. We assessed cardiac function
at baseline (before cardiac surgery) then at 48 hours after MI, and immediately before sacrifice
at 30 days after MI. We utilized a heating pad to keep the body temperature at 37˚C during the
experiment; the temperature was measured using a rectal temperature probe. To determine
the left ventricular function and volume in M-mode, two-dimensional and Doppler echocardi-
ography modes we utilized modified parasternal long-axis and short-axis. We also used M-
mode tracings at the mid-papillary level to estimate the systolic and diastolic parameters, and
Teichholz formula at end-systole and end-diastole to measure the LV volumes. All mice were
anaesthetized using 1%–3% isoflurane during Echocardiography to maintain a heart rate of
450–500 BPM for all echocardiographic acquisitions. Echocardiography imaging and analysis
was performed by a blinded investigator.
Cell culture and hypoxic exposure
The murine macrophage cell line J774 (ATCC, Manassas, VA) was used for the in vitro studies
on the anti-inflammatory effects of AZM. Cells were plated in 6 well plates at concentration
0.3×106 cells/well in media consisting of DMEM, 10% FBS, 1% penicillin/streptomycin, 1%
sodium pyruvate, L-Glutamine, and Glucose. Following cell adhesion (4–6 hours) cells were
treated with AZM (Sigma-Aldrich, St. Louis, MO) at concentration 30 μM or DMSO (SIG-
MA-ALDRICH, St. Louis, MO) as control and incubated over night at 37 C with 5% CO2. To
induce hypoxia-reperfusion injury, cultured cells were established in a gas-tight modular
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chamber (STEMCELL Technologies Inc., Seattle, WA) containing 1% O2, 5% CO2, 94% N2,
or in normal oxygen tension with 20% O2, 5% CO2 as control for 24 hours at 37˚C followed by
reperfusion with 21% O2, 5% CO2 for 24 or 48 hours. Supernatants were collected at the end
of these time points to assess the cytokines level and their ratio (TNF-α and IL-10).
ELISA assays
Protein concentrations of TNF-α and IL-10 are measured using standard ELISA kits (BD Bio-
sciences, San Deigo, CA) according to the manufacturer protocol. Data are presented as indi-
vidual cytokine values and their ratio.
Luminex assay
Plasma was collected according to the above mentioned protocols at days 3, and 7 post-MI.
Inflammatory biomarkers (IL-12, IL-1β, IL-1α, IL-6, TNF-α, MCP-1, MIP-1a and MIP-1b)
were assayed using the Milliplex mouse cytokine magnetic kit (MILLIPLEX MAP for Luminex
xMap Technology, Millipore, USA) according to the manufacturer’s protocol.
Liver and kidney function tests
Plasma was collected according to the above mentioned protocols at days 1, 3, and 7 post-MI.
Samples were sent to ANTEC diagnostic to assay blood urea nitrogen, alanine aminotransfer-
ase (ALT), albumin, and albumin/globulin ratio.
Statistical analysis
Values are expressed as mean ± standard error of mean (SEM). We used unpaired Student t
test or analysis of variance (one-way or multiple comparisons) to estimate differences, as
appropriate. We utilized two-sided Dunnett or Dunn tests for post hoc multiple comparison
procedures, with control samples as the control category. Throughout the analyses, a P value
less than 0.05 was considered statistically significant. All statistical analyses were performed
using the Prism 7 software package (GraphPad, La Jolla, CA).
Results
AZM shifts macrophages away from the pro-inflammatory towards the
reparative state post-MI
Macrophages are the predominant inflammatory cells type in cardiac tissue after cardiac
injury, regulating its healing at multiple phases [21]. It is well established that AZM can modu-
late inflammation through shifting macrophages towards the reparative phenotype [11–14].
To date, the effect of AZM on the inflammatory response after MI at the level of macrophages
has not been characterized. We analyzed the phenotype of macrophages in cardiac tissue at
several time points following induction of MI using flow cytometry (Fig 1A). We detected a
significant reduction in the pro-inflammatory macrophages (CD45+/Ly6G-/F4-80+/CD86+) at
1 day following MI with AZM treatment (Fig 1B). This effect was associated with a significant
increase in the reparative macrophages (CD45+/Ly6G-/F4-80+/CD206+) at day 1 and 3 after
MI (Fig 1C). Overall, the ratio between pro- and anti-inflammatory macrophages was reversed
towards an anti-inflammatory state with AZM treatment, particularly in the early phase after
MI (Fig 1D).
Under physiological conditions, resident macrophages maintain tissue homeostasis [2].
However, after injury such as MI, monocytes infiltrate the heart and differentiate into macro-
phages. Monocytes contribute to tissue healing and repair through coordinated activities of
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different monocyte subpopulations (Ly6Chi vs. Ly6Clo) [22, 23]. We assessed monocyte sub-
populations (Ly6Chi vs. Ly6Clo) after MI in the PB and heart (Fig 2A). While we did not notice
significant differences between blood monocyte subsets in AZM vs. vehicle treated mice, we
detected a significant reduction in the Ly6Chi (pro-inflammatory) monocytes (CD45+/Ly6C/
Ghi/CD115hi) in cardiac tissue after MI with AZM treatment (Fig 2B). There was no signifi-
cant difference in the Ly6Clo (anti-inflammatory) monocytes in cardiac tissue with AZM treat-
ment. This suggests a reduction in pro-inflammatory monocyte infiltration to the heart or a
reduction in their polarization in the myocardium. Since maintained Ly6Chi monocytes
impair healing after MI [23], these results imply that AZM treatment reduces detrimental
inflammatory response following myocardial ischemia.
AZM downregulates pro-inflammatory cytokines while upregulating anti-
inflammatory cytokines following cardiac injury
Macrophages have distinctive cytokine profiles based on their inflammatory status. Pro-
inflammatory macrophages are potent generators of toxic effector molecules (reactive oxygen
Fig 2. AZM therapy reduces cardiac inflammatory monocytes after MI. Representative FACS plots demonstrating the gating strategy for Ly6Chi (CD45+/CD115hi/
Ly6-Chi) and Ly6Clo (CD45+/CD115hi/Ly6-Clo) monocytes (Panel A). Quantitative analyses of monocyte subpopulations in PB and heart tissue demonstrating no
significant changes in PB monocyte subpopulations but significant reduction in cardiac Ly6Chi population throughout the different time points after MI in AZM treated
mice (Panel B) (n = 4 MI and 3 sham mice/group/time point, P<0.05 and P<0.01 compared to vehicle controls). Data presented as mean ± SEM. AZM, azithromycin;
PB, peripheral blood.
https://doi.org/10.1371/journal.pone.0200474.g002
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species, nitric oxide) and pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) [7]. Conversely,
reparative macrophages produce anti-inflammatory molecules (TGF-β and IL-10) and express
scavenger, mannose, and galactose-type receptors [8, 9]. We conducted in vitro studies to
examine the effect of hypoxia/reperfusion injury on the phenotype of J774 macrophages in the
presence or absence of AZM. Following 24 hours hypoxia and reperfusion, we noted signifi-
cant shift in macrophage cytokine production towards a pro-inflammatory phenotype with
higher TNF-α levels compared to IL-10 levels. AZM treatment shifted the cytokine production
towards an anti-inflammatory pattern with significant increase in IL-10/TNF-α ratio (Fig 3).
We also examined the effect of AZM on cytokine expression following MI in the in vivo
studies. Our data confirm the change towards the anti-inflammatory state with AZM treat-
ment. In heart tissue, AZM treatment was associated with significant reductions in the gene
expression of iNOS and inflammatory cytokines (MCP-1, TNF-α, IL-6, and IL-1β) while the
anti-inflammatory cytokines/macrophage modulatory factors (TGF-β and IL-4, PPARγ and
YM1) were increased (Fig 4A). A similar trend was noted in the gene expression of pro- and
anti-inflammatory cytokines in PB cells at the same time points (Fig 4B). These gene expres-
sion results are corroborated by IHC and ELISA studies of the heart and plasma, respectively.
Three days after MI, we quantified IL-1β and YM1 levels in the peri-infarct zone. IL-1β was
remarkably downregulated with a concomitant elevation in YM1 in AZM treated mice com-
pared to the control group (S2 Fig). In plasma, levels of inflammatory cytokines (IL-12, IL-1β,
IL-1α, IL-6, TNF-α, MCP-1, MIP-1a and MIP-1b) were suppressed on days 3 and 7 post-MI as
assessed by the Luminex assay (S3 Fig). Overall, these results imply that AZM treatment mod-
ulates the inflammatory response following myocardial ischemia by attenuating the pro-
inflammatory changes and enhancing anti-inflammatory/reparative cytokine production.
AZM treatment is associated with alternative macrophages activation in
the peri-infarct region
The balance between pro- and anti-inflammatory macrophages in the peri-infarct region plays
an important role in infarct expansion and adverse cardiac remodeling [2, 4, 21, 24]. To
Fig 3. AZM therapy reduces the production of inflammatory cytokines in macrophages subjected to ischemia/reperfusion injury. Quantitative analyses of pro-
inflammatory cytokine, TNF-α, and the anti-inflammatory cytokine, IL-10, production from J774 macrophages subjected to 24 hypoxia followed by 24 and 48 hours of
reperfusion. The analysis demonstrates reduction of TNF- α compared to vehicle both at 24 and 48 hours. No significant changes were noted in IL-10 production.
Overall, the IL-10/TNF-α ratio was significantly higher in macrophages treated with AZM (Panel B) (two independent experiments and 4 replicates/time point, P<0.05,
P<0.001 and  P<0.0001 compared to vehicle controls). Data presented as mean ± SEM. AZM, azithromycin; IL-10, interleukin 10; TNF-α, tumor necrosis factor-
alpha.
https://doi.org/10.1371/journal.pone.0200474.g003
Azithromycin reduces cardiac damage after myocardial infarction
PLOS ONE | https://doi.org/10.1371/journal.pone.0200474 July 12, 2018 10 / 25
Fig 4. AZM treatment exerts immunomodulatory effects on cytokines expression following MI. mRNA expression of pro-inflammatory cytokines in HT (Panel
A) and PB (Panel B), demonstrate significant reduction in gene expression of these cytokines in the early inflammatory phase following injury with AZM therapy
compared to vehicle controls (red line demarcates the level of gene expression in sham operated mice). The mRNA expression of anti-inflammatory cytokines is
augmented with AZM therapy compared to vehicle control (n = 4 mice/group/time point, P<0.05, P<0.01, P<0.001 and  P<0.0001 compared to vehicle
controls). Data presented as mean ± SEM. AZM, azithromycin; HT, heart; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-4, interleukin 4; iNOS, inducible nitric
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evaluate the impact of AZM on the activation state of macrophages in the peri-infarct region,
we quantified pro-inflammatory (CD86+) and anti-inflammatory (CD206+) macrophages 3
days post-MI using immunohistochemistry. Our results confirmed the shift towards an anti-
inflammatory state with AZM treatment. AZM-treated mice had significantly lower numbers
of CD86+ cells and higher numbers of CD206+ cells (Fig 5). Importantly, the pro-inflamma-
tory/reparative macrophage ratio were decreased robustly in the AZM treated compared to the
vehicle group. Of note, macrophage inflammatory state is a spectrum from the pro- to the
anti-inflammatory phenotypes. Nonetheless, we used the same strategy for assessing each pop-
ulation quantitatively to avoid any bias. We counted CD86 and CD206 separately and this
could have led to double counting of cells in each category. These findings are in agreement
with our flow cytometry data and implicate a potential therapeutic role for AZM in reducing
post-MI cardiac inflammatory changes.
AZM reduces neutrophil counts after cardiac ischemia through enhancing
apoptosis
In acute inflammation, neutrophils are key players in removing pathogens and debris, thus
contributing to the return of normal tissue homeostasis [25]. Evolutionary mechanisms have
developed to limit the initial inflammatory response after MI. These pathways include a robust
switch of macrophages towards anti-inflammatory phenotype following ingestion of apoptotic
neutrophils [26]. Indeed, prior studies have implicated the ingestion of apoptotic cells as a
mechanism for the anti-inflammatory changes observed with AZM [27]. While our data as
well as others have shown that AZM induces alternative polarization of macrophages towards
the anti-inflammatory state, the mechanism of these changes is not entirely clear. We hypothe-
sized that AZM promotes neutrophil apoptosis which likely initiates the anti-inflammatory
changes. In support of this hypothesis, prior reports have confirmed the pro-apoptotic effects
of macrolides on neutrophils [28, 29]. We therefore analyzed neutrophil numbers (CD45+/
CD115lo/Ly6G/Clo) using the gating strategy outlined in Fig 2A in the heart and PB via flow
cytometry. Treatment with AZM resulted in significant reductions of neutrophil counts in car-
diac tissue and PB in the early phase after MI (Fig 6A). To further investigate the mechanism
associated with neutrophil count reduction, we examined neutrophil apoptosis using Annexin
V and PI staining in cardiac tissue using flow cytometry. AZM treatment was associated with a
significant increase in the percentage of apoptotic neutrophils in the early inflammatory phase
after MI compared to vehicle-treated mice (Fig 6B and 6C). Our findings indicate that AZM
treatment reduces neutrophil numbers after cardiac injury through pro-apoptotic effects,
which could account for its post-MI immunomodulatory effect.
AZM diminishes cardiac cell death and scar size while promoting
angiogenesis following cardiac ischemic injury
Alternatively activated macrophages are master regulators of the healing process after MI by
regulating cardiomyocyte apoptosis, collagen deposition, and angiogenesis in the peri-infarct
regions [30]. To determine the effect of AZM effects on programmed cell death in the heart
post-MI, we investigated cleaved caspase-3 positive staining of cells in the infarct zone, peri-
infarct border, and remote (normal) zones 3 days post-MI. We found that apoptosis was sig-
nificantly reduced within the infarct and border regions in the AZM-treated group compared
oxide synthase; MCP-1, monocyte chemoattractant protein-1; PB, peripheral blood; PPARγ, peroxisome proliferator-activated receptor gamma; TGF-1β, tissue
growth factor 1 beta; TNF-α, tumor necrosis factor-alpha; YM1 (Chil3), chitinase-like 3.
https://doi.org/10.1371/journal.pone.0200474.g004
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to vehicle-treated group (Fig 7). In order to confirm our caspase 3 staining results, we per-
formed TUNEL assay in the peri-infarct region. The results were consistent with the caspase 3
assay (S4 Fig), suggesting enhanced survival of cardiac cells, likely driven by AZM. These data
corroborate the immunohistochemistry and real-time PCR results, demonstrating significant
reduction in pro-apoptotic cytokines such as TNF-α. We then assessed the effect of AZM ther-
apy on the infarct size using morphometric assessments on Masson’s trichrome-stained cross-
sections from the hearts (30 days post-MI). We observed significantly smaller scar size in mice
treated with AZM compared to those treated with vehicle (Fig 8A and 8B). These data indicate
that AZM protects the infarcted heart from the adverse cardiac remodeling that occurs chroni-
cally after ischemia.
Alternatively activated macrophages produce multiple cytokines (including pro-angiogenic
factors) that can enhance regeneration [8, 9]. Angiogenesis is regarded as a major stimulator
of tissue recovery in the heart after ischemic injury. To examine the vessels density in the peri-
infarcted areas between groups, we assessed quantified isolectin (a marker of endothelial cells
in blood vessels) 30 days following MI. Mice treated with AZM had significantly higher capil-
lary density in the peri-infarct region compared to vehicle-treated mice (Fig 8C and 8D).
Taken together with the results detailed in Fig 7, AZM treatment reduces scar size after MI,
which could be explained by the reduction in cellular apoptosis and enhanced angiogenesis in
the ischemic heart.
AZM preserves cardiac function, reduces adverse remodeling and improves
survival post-MI
Loss of balance between inflammatory and reparative phases post-MI can result in adverse car-
diac remodeling and eventually systolic HF [4]. Our data suggest an immunomodulatory role
for AZM on the heart post-MI. To examine the translation of these cellular effects on cardiac
function, echocardiography was carried out on AZM and vehicle treated mice at baseline, and
2 and 30 days after MI. We observed preservation of LV ejection fraction as well as fractional
shortening in AZM treated compared to vehicle mice (Fig 9A–9C). We also observed similar
effects on parameters of LV remodeling such as LV end-systolic and end-diastolic diameters
(Fig 9D and 9E). In agreement with the noted reduction in scar size, we observed significantly
less deterioration in infarct wall thickness in AZM treated group compared to controls (Fig
9F). Therefore, the beneficial effect of AZM extends beyond the enhancements in the inflam-
matory balance after MI to a favorable recovery of LV functional and remodeling parameters
as summarized in S2 Table. Additionally, survival rates reflect these AZM-mediated functional
improvements with a marked reduction in mortality in AZM-treated mice (Fig 9G).
Discussion
Cardiac inflammation is a crucial component of the recovery phase after MI. However, a tug-
of-war between pro- and anti-inflammatory forces in the ischemic myocardium impacts car-
diac recovery. Reversing the pro-inflammatory forces after MI can enhance cardiac recovery
and survival. In this study, we provide first evidence that the macrolide, AZM, exerts
Fig 5. AZM treatment enhances alternative macrophage activation in the peri-infarct border of the injured heart. Immunohistochemical assessment of the content of
pro-inflammatory (CD86+) and reparative macrophages (CD206+) markers 3 days post-MI. Panel A shows representative images from vehicle- and AZM-treated mice
demonstrating higher density of CD86+ compared to CD206+ cells in the peri-infarct border in vehicle-treated mice. White line demarcates the infarct border. Panel B
shows quantitative assessment of CD86+, CD206+ and the markers ratio 3 days post-MI. The difference in pro-inflammatory and anti-inflammatory macrophages lead to
a significant shift towards an anti-inflammatory state and the reduction in their ratio in AZM-treated mice (n = 4 animals/group, P<0.05 and P<0.0001 compared to
vehicle controls). Scale bars represent 50 μm. Data presented as mean ± SEM. AZM, azithromycin; HPF, high power field.
https://doi.org/10.1371/journal.pone.0200474.g005
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Fig 6. Cardiac neutrophils are reduced with AZM treatment due to apoptosis. Panel A summarizes the quantitative assessment of neutrophil (CD45 +/CD115lo/
Ly6G-Clo) numbers and demonstrates significant reduction in the AZM-treated group relative to controls in the heart and peripheral blood during the early
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immunomodulatory effects on macrophages after MI shifting them towards anti-inflamma-
tory phenotype. This is demonstrated by significant reduction in pro-/anti-inflammatory mac-
rophage ratio and pro-inflammatory genes expression in parallel with significant elevation in
anti-inflammatory gene expression. These immunomodulatory effects resulted in reduced
apoptosis and scar size, enhanced cardiac functional recovery, and improved survival. Taken
together, AZM represents a novel and clinically available target for reducing cardiac inflamma-
tion and damage following MI.
The immunomodulatory effects of AZM after MI appear to be multifactorial including
direct effects on macrophages as well as pro-apoptotic effects on neutrophils. It is well accepted
that neutrophils play a critical role in tissue healing following MI through debris clearance
from the injury site [31]. However, prolonged neutrophil accumulation in the heart post-MI is
considered deleterious [32, 33]. On the other hand, aggressive neutrophil depletion following
MI can disturb the healing process, leading to impaired functional recovery [34]. Clinical data
suggest that a delay in neutrophil apoptosis after MI contributes to the exaggerated inflamma-
tory response [35]. Here, we show that AZM enhances neutrophil apoptosis in cardiac tissue
after MI, which could explain the reduction in neutrophil counts in our studies. This is in
agreement with other reports in the literature that suggest a pro-apoptotic effect of macrolides
on neutrophils [28, 36]. The pro-apoptotic effect of AZM is most noticeable on the first day
after MI. Importantly, studies have shown that AZM is more concentrated in polymorphonu-
clear leukocytes, which will induce apoptosis in these cells through arresting cell cycle in G2/M
[37]. Engulfing apoptotic neutrophils by macrophages stimulates the anti-inflammatory
response through blocking pro-inflammatory cytokines and enhancing anti-inflammatory
cytokines (IL-10 and TGF-β) and pro-resolving lipid mediators [38].
In addition to its effects on neutrophil apoptosis, AZM can have direct effects on macro-
phages. Our in vitro results indicate that AZM therapy attenuates the inflammatory changes
seen in macrophages subjected to hypoxia/reperfusion injury. In addition, induction of pro-
grammed cell death in neutrophils results in decrease in the production of inflammatory cyto-
kines and chemokines [39], as demonstrated in our study. Indeed, our experiments show that
AZM treatment decreased the expression of MCP-1 which promotes Ly6Chi cells recruitment
to the infarcted tissue. Ly6Chi monocytes differentiate into pro-inflammatory macrophages in
the peri-infarct border which eventually contribute to adverse cardiac remodeling [40]. Fur-
thermore, through the reduction in neutrophil count and modulation of macrophage pheno-
type, the production and deleterious effects of pro-inflammatory cytokines such as TNF-α, IL-
1β, and IL-6 were diminished [41]. In parallel to the decreased pro-inflammatory cytokines,
we observed significant increase in anti-inflammatory cytokines such as TGF-β and IL-4
which have been linked to favorable cardiac remodeling and functional recovery after MI [42].
The immunomodulatory effects of AZM have been demonstrated in various inflammatory
and tissue injury scenarios [14, 43]. Among them, acute stroke and spinal cord injury have
close resemblance to the inflammatory reactions (biphasic macrophage response and chemo-
kine profile) happening post-cardiac injury [15, 44]. AZM treatment after spinal cord injury
led to significant decrease in pro-inflammatory macrophages and increase in anti-inflamma-
tory macrophages [13, 43]. Interestingly, and in accordance with our data, the shift in macro-
phage phenotype was associated with marked functional improvements in mice. The exact
inflammatory stage post-MI. Panel B illustrates the flow cytometry analyses of neutrophil populations stained against annexin V and PI showing higher percentage of
early apoptotic neutrophils in AZM-treated mice. Panel C summarizes the quantitative assessment of early apoptotic neutrophils and demonstrates significantly
higher percentage in the heart in the AZM-treated group during the early stage following MI (n = 4 mice/group/time point, P<0.05 compared to vehicle controls).
Data presented as mean ± SEM. AZM, azithromycin; HT, heart; PB, peripheral blood; PI, propodium Iodide.
https://doi.org/10.1371/journal.pone.0200474.g006
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Fig 7. AZM reduces apoptosis post-infarction. Panel A shows representative light microscope images of cleaved caspase-3 staining for infarcted and
border regions in AZM- and vehicle-treated mice 3 days after MI. Quantitative analyses (Panel B) of apoptosis reveal a remarkable reduction in
caspase-3 activation in the infarct and border regions of AZM-treated group compared to the control group (n = 4 animals/group, P<0.01 compared
to vehicle controls). Scale bars represent 100 μm. Data presented as mean ± SEM. AZM, azithromycin; HPF, high power field.
https://doi.org/10.1371/journal.pone.0200474.g007
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Fig 8. AZM treatment reduces scar size and enhances angiogenesis after myocardial injury. Representative
Masson’s trichrome staining at 30 days after myocardial injury in vehicle- and AZM-treated groups (Panel A).
Azithromycin reduces cardiac damage after myocardial infarction
PLOS ONE | https://doi.org/10.1371/journal.pone.0200474 July 12, 2018 18 / 25
molecular mechanisms through which AZM exerts its immunomodulatory effects are not fully
understood. However, transcription factors such as NF-kB and AP-1 are likely targets [45].
Our unpublished data suggest that AZM reduces NF-kB activation through decreasing the
translocation of phospho-p65 to the nucleus. Furthermore, there is a simultaneous increase in
IKKβ and IκBα with AZM therapy. This does not exclude immunomodulatory actions medi-
ated through other intracellular signaling pathways [45].
Macrophages are essential players in the myocardial environment post-MI and their role
extends beyond the inflammatory phase to tissue regeneration and healing [46, 47]. The heart
possesses a remarkable regenerative capacity in the early stages of postnatal life, an ability lost
by day 7 after birth [48, 49]. It has been postulated that this regenerative capacity is related to
the naivety of the immune system in which macrophage modulation plays a central role [30].
Indeed, anti-inflammatory macrophages have been shown to interact with stem cells following
cardiac injury leading to enhance cardiac recovery [4]. Overall, AZM therapy is associated
with higher numbers of anti-inflammatory macrophages (CD206+ cells) after MI with the
majority of changes occurring in the peri-infarct region as shown in our immunohistochemis-
try data. This phenotypic shift is associated with smaller scar, better cardiac function, and
enhanced angiogenesis after MI. Additionally, we observed a significant reduction in apoptotic
heart cells in both infarct and peri-infarct areas at day 3 post-MI, which could be attributed to
the survival factors released from reparative macrophages [42, 50]. In summary, the early shift
in macrophages towards the reparative phenotype by AZM treatment can limit acute ischemic
damage and promote chronic cardiac recovery.
The balance between macrophage phenotypes is reversible [21] and can be therapeutically
harnessed to enhance cardiac healing after ischemic injury. Animal studies show that early
interventions aimed at altering macrophage activation state or shifting the balance towards the
anti-inflammatory phenotype can substantially reduce the risk of HF development [4, 51, 52].
Kain et al initiated a phenotypic switch in macrophages after myocardial injury by using either
free or encapsulated 15-epi-Lipoxin A4. They demonstrated upregulation of the reparative
macrophages as well as the anti-inflammatory/macrophage modulatory genes (Mrc-1, Ym-1,
Arg-1). Moreover, cardiac function was improved in 15-epi-Lipoxin A4 treated mice com-
pared to controls [52]. These findings were confirmed in multiple studies using different thera-
peutic approaches, including formyl peptide receptor 2 [51], cardiosphere-derived cells [4],
and endogenous Annexin-A1 [53]. However, studies on alternative macrophage activation in
MI utilized experimental therapeutics with limited safety data in humans. Conversely, our
strategy of using AZM is more clinically relevant and can be safely translated to human
studies.
Healing and remodeling after MI are fundamentally regulated by the inflammatory path-
ways. Modulating the inflammatory response post-MI is an elusive target as studies have
shown that complete inhibition of inflammation is rather harmful [54]. Indeed, therapeutic
interventions targeting the systemic inflammatory pathways have yielded limited success in
pre-clinical and clinical studies [54]. Delayed healing and development of ventricular aneu-
rysm were reported with glucocorticosteroids, and their uses should be avoided post-MI [55].
Quantitative analysis of scars as percentage of LV area shows significant reduction in AZM group relative to the
control group (Panel B) (vehicle-treated, n = 15 vs. AZM-treated, n = 12, P<0.01 compared to vehicle controls).
Representative isolectin staining (Green) for capillary density in the peri-infarct region in AZM- and vehicle-treated
animals demonstrates higher capillary density in AZM group compared to control (Panel C). Quantitative analysis of
capillary density confirms the higher angiogenesis rate and capillary density in AZM-treated group (Panel D) (n = 4
animals/group, P<0.01 compared to vehicle controls). Scale bars represent 50 μm. Data presented as mean ± SEM.
AZM, azithromycin; MI, acute myocardial infarction; LV, left ventricular.
https://doi.org/10.1371/journal.pone.0200474.g008
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Fig 9. AZM treatment improves chronic cardiac remodeling and survival post-MI. 30 day following MI, transthoracic echocardiography using M-Mode
(Panel A) and 2D echocardiography was performed on AZM- and vehicle-treated animals to evaluate left ventricular function and remodeling parameters.
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On the other hand, NSAIDs use in coronary artery disease patients has been correlated with
higher mortality and recurrent myocardial infarction [56]. Selective targeting of inflammatory
mediators such as IL-1β using selective monoclonal antibodies demonstrated success in clinical
studies, albeit with high cost and modest benefit [57]. Therefore, strategies aimed at modulating
the inflammatory response rather than its suppression provide promising therapeutic modali-
ties. In this study, we show that AZM as a small immunoregulatory molecule provides more
specific modulation to the post-MI inflammation through increasing the abundance of anti-
inflammatory macrophages without completely blunting the pro-inflammatory mediators.
In this study, we initiated AZM 3 days prior to MI to ensure appropriate steady-state levels
at the time of injury [14]. Based on published literature [45], we anticipate rapid accumulation
of AZM in macrophages and fast immunomodulatory actions. Hence, initiating AZM follow-
ing MI could be beneficial as well and this is currently being studied in our lab. Another limita-
tion in our study is the use of relatively higher dose of AZM (160mg/kg/day) than the clinically
prescribed dose (10-45mg/kg) [43]. As a proof of concept, we aimed to achieve a dose consis-
tent with our in vitro studies. However, multiple human studies have demonstrated AZM
safety at higher doses and its wide therapeutic window. Given the allometric scaling on AZM,
lower doses than those used in our study may be effective in humans [10, 47]. Finally, we
sought to examine the extremes of macrophage polarization by quantifying the pro- and anti-
inflammatory macrophages based on gene expression and surface markers. While this is a
helpful approach for examining the effects of AZM, we acknowledge that it oversimplifies the
macrophage landscape and categorizes them into only two main groups (pro- and anti-inflam-
matory) which may lead to overestimating either of the categories [58]. Future studies are war-
ranted to provide a comprehensive examination of the effect of AZM on the various
macrophage subtypes after MI.
Conclusions
Cardiac inflammatory changes following MI are mediated, at least in part, by pro-inflamma-
tory macrophages, which have detrimental effects on cardiac function and survival. This is the
first study to demonstrate the efficacy of AZM as an immunomodulatory pharmacological
agent for macrophages after MI. Our results indicate that the anti-inflammatory effects of
AZM are related to its direct effects on macrophages and its pro-apoptotic effects on neutro-
phils. Systematic assessment of cardiac and systemic changes demonstrates that the beneficial
effects of AZM result in significant reduction in scar size, adverse cardiac remodeling, cardiac
function, and survival post cardiac ischemia. AZM has a wide therapeutic window, can be
administered orally, has low side effect profile and has been approved for human use. These
criteria make it an ideal agent for novel and effective therapeutic interventions to improve sur-
vival and reduce HF following MI in humans.
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